[Changes in lipid tissue redistribution and metabolic disorders in HIV positive patients treated with protease inhibitors].
Significant decrease in AIDS mortality rate has been noted since 1996 when proteases inhibitors (PI) were introduced into vast use. Unfortunately they revealed major side effects of which lipodystrophy (L) turned out to be very serious due to various clinical implications consequently worsening prognosis of HIV-positive patients treated with HAART (highly active antiretroviral therapy). Redistribution of lipid tissue in many cases was a reason of switching the PI-therapy, though very effective, into PI-sparing therapy of non-nucleoside reverse transcriptase inhibitors (NNRTI) and nucleoside reverse transcriptase inhibitors (NRTI), doubtlessly confining future therapeutic options. This review presents our to date knowledge on clinical aspects, pathogenesis, treating and further consequences of these changes.